MP74-09 THE PREVALENCE OF EXTREME SERUM PROSTATE SPECIFIC ANTIGEN LEVELS DURING THE COVID-19 PANDEMIC
Notice bibliographique
Résumé
You have accessJournal of UrologyProstate Cancer: Detection & Screening VI (MP74), Moderated Poster 741 May 2024MP74-09 THE PREVALENCE OF EXTREME SERUM PROSTATE SPECIFIC ANTIGEN LEVELS DURING THE COVID-19 PANDEMIC Amanda E. Hird, Rano Matta, Refik Saskin, Erind Dvorani, Sarah Neu, Sender Herschorn, and Robert K. Nam Amanda E. HirdAmanda E. Hird , Rano MattaRano Matta , Refik SaskinRefik Saskin , Erind DvoraniErind Dvorani , Sarah NeuSarah Neu , Sender HerschornSender Herschorn , and Robert K. NamRobert K. Nam View All Author Informationhttps://doi.org/10.1097/01.JU.0001008632.59099.b9.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The COVID-19 pandemic resulted in decreased prostate specific antigen (PSA) testing for prostate cancer screening and its impact remains uncharacterized. Our objective was to compare incident PSA testing rates, PSA levels, and prostate cancer treatment rates before and during the pandemic after the state of emergency (SoE) was declared. METHODS: This was a population-based, retrospective cohort study among men 50-80 years of age in Ontario, Canada undergoing incident PSA testing from November 23, 2018 until July 9, 2021. The period of the province-wide SoE was declared on March 17, 2020 due to the rise of COVID-19 infection rates. Working backwards and forwards from this date, 30-day time periods were constructed, beginning November 23, 2018 and ending July 9, 2021 during which incident PSA testing rates were measured. Our primary outcome was the rate of incident PSA testing before and after the SoE declaration. Secondary endpoints included comparison of incident PSA levels and prostate cancer treatment rates. RESULTS: We identified 835,402 men who underwent incident PSA testing. There was a 20% decrease in PSA testing during the pandemic (RR=0.80, 95%CI: 0.80-0.81, p<0.001), compared to before. There was a higher proportion of extreme PSA levels after the SoE with a higher proportion of patients with a PSA greater than 20 ng/mL (rate ratio=1.63 95%CI: 1.54-1.73, p<.0001) and greater than 100 ng/mL (rate ratio=1.98, 95%CI: 1.77-2.20, p<.0001), compared to before. This effect was highest for those aged 50-59 years. More patients required active treatment (5,201, 59.5% prior to the pandemic vs. 5,072, 64.2%, p<0.001 after the SoE declaration), including the use of androgen deprivation therapy alone or in combination with radiation. CONCLUSIONS: The COVID-19 SoE resulted in patients experiencing a two-fold increase in the risk of having an extreme PSA level (>100 ng/mL) and higher odds of treatment for advanced disease. This data will provide more information to decision-makers when considering future pandemic planning. Source of Funding: This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long–Term Care (MOHLTC). This study also received funding from the Ajmera Family Chair in Urologic Oncology awarded to RKN © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1196 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Amanda E. Hird More articles by this author Rano Matta More articles by this author Refik Saskin More articles by this author Erind Dvorani More articles by this author Sarah Neu More articles by this author Sender Herschorn More articles by this author Robert K. Nam More articles by this author Expand All Advertisement PDF downloadLoading ...
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,002 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,001 | 0,001 |
| Études des sciences et des technologies | 0,001 | 0,000 |
| Communication savante | 0,001 | 0,001 |
| Science ouverte | 0,000 | 0,001 |
| Intégrité de la recherche | 0,000 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,007 | 0,001 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».